Last reviewed · How we verify
Telmisartan/Amlodipine+Hydrochlorothiazide
Telmisartan is an angiotensin II receptor antagonist, while amlodipine is a calcium channel blocker, and hydrochlorothiazide is a thiazide diuretic.
Telmisartan is an angiotensin II receptor antagonist, while amlodipine is a calcium channel blocker, and hydrochlorothiazide is a thiazide diuretic. Used for Hypertension, Chronic stable angina.
At a glance
| Generic name | Telmisartan/Amlodipine+Hydrochlorothiazide |
|---|---|
| Sponsor | IlDong Pharmaceutical Co Ltd |
| Drug class | Angiotensin II receptor antagonist, Calcium channel blocker, Thiazide diuretic |
| Target | Angiotensin II receptor, L-type calcium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Telmisartan works by blocking the action of angiotensin II, a potent vasoconstrictor, which leads to vasodilation and reduced blood pressure. Amlodipine blocks the influx of calcium ions into smooth muscle cells, causing vasodilation and reduced blood pressure. Hydrochlorothiazide increases the excretion of sodium and water, leading to decreased blood volume and reduced blood pressure.
Approved indications
- Hypertension
- Chronic stable angina
Common side effects
- Edema
- Dizziness
- Headache
Key clinical trials
- Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension (PHASE4)
- INTERVENCION Trial (PHASE4)
- Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy in Real-world Japanese Therapeutic Practice
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Coronavirus (COVID-19) ACEi/ARB Investigation (PHASE4)
- To Evaluate Real-world Safety, Effectiveness and Appropriate Use of Micatrio® Combination Tablets Treatment in Patients With Hypertension
- A Study to Evaluate the Drug-drug Interaction Between Telmisartan, Amlodipine and Hydrochlorothiazide (PHASE1)
- Non-invasive Haemodynamic Assessment in Hypertension (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: